CN115286697B - 一种双重靶向化合物及其制备方法和应用 - Google Patents
一种双重靶向化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN115286697B CN115286697B CN202211201081.2A CN202211201081A CN115286697B CN 115286697 B CN115286697 B CN 115286697B CN 202211201081 A CN202211201081 A CN 202211201081A CN 115286697 B CN115286697 B CN 115286697B
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- radionuclide
- targeting compound
- dual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 86
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 56
- 102000006495 integrins Human genes 0.000 claims abstract description 45
- 108010044426 integrins Proteins 0.000 claims abstract description 45
- 230000008685 targeting Effects 0.000 claims abstract description 40
- 230000009977 dual effect Effects 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000002018 overexpression Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 5
- 230000002285 radioactive effect Effects 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 6
- 238000006482 condensation reaction Methods 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- QSJTUXCBPTVKQZ-JEDNCBNOSA-N (2s)-pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.N#C[C@@H]1CCCN1 QSJTUXCBPTVKQZ-JEDNCBNOSA-N 0.000 claims description 3
- UVKYGKPXDDWMIV-UHFFFAOYSA-N 6-hydroxyquinoline-4-carboxylic acid Chemical compound C1=C(O)C=C2C(C(=O)O)=CC=NC2=C1 UVKYGKPXDDWMIV-UHFFFAOYSA-N 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 229960002989 glutamic acid Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- SJMDMGHPMLKLHQ-UHFFFAOYSA-N tert-butyl 2-aminoacetate Chemical compound CC(C)(C)OC(=O)CN SJMDMGHPMLKLHQ-UHFFFAOYSA-N 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 2
- NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical group C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 claims description 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims description 2
- OZMXZVCAXAQCHJ-UHFFFAOYSA-N 3-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]ethoxy]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCOCCOCCC(O)=O OZMXZVCAXAQCHJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 208000005072 Oncogenic osteomalacia Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000007859 condensation product Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 201000009377 thymus cancer Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 10
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 230000014759 maintenance of location Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000009206 nuclear medicine Methods 0.000 abstract description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000001819 mass spectrum Methods 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- 229940125758 compound 15 Drugs 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- 108010073466 Bombesin Receptors Proteins 0.000 description 3
- 102000047481 Gastrin-releasing peptide receptors Human genes 0.000 description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000013076 target substance Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- XOYLJNJLGBYDTH-UHFFFAOYSA-M chlorogallium Chemical compound [Ga]Cl XOYLJNJLGBYDTH-UHFFFAOYSA-M 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000013170 computed tomography imaging Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229910052733 gallium Inorganic materials 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- -1 amino tert-butyl Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域
本发明涉及核医学与分子影像学领域,具体地涉及一种放射性核素标记的成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物,以及制备方法和所述化合物在诊断或治疗以FAP和/或整合素αvβ3过度表达为特征的疾病中的用途。
背景技术
成纤维细胞活化蛋白( Fibroblast activation protein,FAP) 是一种膜丝氨酸肽酶,表达于肿瘤间质活化的成纤维细胞表面,在肿瘤的发生发展过程中发挥重要作用。既往研究表明,FAP在正常人组织中一般无表达,但是选择性地高表达于 90% 以上的上皮恶性肿瘤的基质成纤维细胞表面,包括乳腺癌、卵巢癌、肺癌、结直肠癌、胃癌和胰腺癌等。整合素αvβ3(integrin αvβ3)是位于细胞表面的异源二聚体受体,在正常血管内皮和上皮细胞很少表达,但在肺癌、骨肉瘤、成神经细胞瘤、乳腺癌、前列腺癌、膀胱癌、胶质母细胞瘤及浸润性黑色素瘤等多种实体肿瘤细胞表面有高水平的表达,而且在所有肿瘤组织新生血管内皮细胞膜有高表达,提示整合素αvβ3在肿瘤生长、侵袭和转移过程中起着关键作用。含精氨酸-甘氨酸-天冬氨酸(RGD)序列的多肽能与整合素αvβ3特异性结合。鉴于FAP和整合素αvβ3在肿瘤中的广泛表达及重要作用,FAP和整合素αvβ3已成为肿瘤显像和治疗的重要靶点。
为了进一步提高肿瘤的诊断和治疗效率,现有技术中对两个靶点同时具备亲和力的双重靶向探针已有所开发。例如,Anna Orlova等人报道了针对对前列腺特异性膜抗原(PSMA) 和胃泌素释放肽受体 (GRPR) 同时具有亲和力的双重靶向探针。由于PSMA和GRPR同时在前列腺中高表达,因此这种双重靶向探针存在的缺点是仅应用于前列腺癌的放射诊断与治疗,无法应用于其他肿瘤。
发明内容
由于FAP和整合素αvβ3主要分布在肿瘤基质细胞和新生血管中,因此在多种肿瘤类型中同时高表达,是开发“泛肿瘤”双重靶向探针的理想靶点。考虑到肿瘤的异质性,为了能够进一步提高肿瘤的诊断和治疗效率,有必要开发一种针对FAP和整合素αvβ3两种靶点均可发挥靶向作用的靶向化合物。这种双重靶向化合物需要对两个靶点同时具备高亲和力,实现协同靶向肿瘤中的FAP靶点及整合素αvβ3靶点,同时在体内需要具有优异的药物代谢动力学性质,提升肿瘤摄取和肿瘤滞留时间。基于这种双重靶向化合物的放射性核素标记的双重靶向化合物,能够同时利用FAP靶点及整合素αvβ3靶点,提升肿瘤中的有效受体数量和利用效率,从而解决提升阳性肿瘤检出效率和/或治疗效率的问题。
为了解决上述问题,本发明的首要目的在于:开发一种新的化合物结构可协同靶向肿瘤中的FAP靶点及整合素αvβ3靶点,以提升药物在肿瘤中的摄取及滞留时间。
本发明的另一个目的在于:提供制备所述的新化合物的方法,以通过方便易得的合成路线合成可协同靶向肿瘤中的FAP靶点及整合素αvβ3靶点的化合物。
本发明的再一个目的在于:提供所述化合物在诊断或治疗以FAP和/或整合素αvβ3过度表达为特征的疾病中的应用。
本发明的上述目的通过以下技术方案实现。
第一方面,本发明提供一种可靶向FAP和整合素αvβ3的双重靶向化合物,其结构中同时包含FAP和整合素αvβ3的特异性结合配体结构,所述的化合物结构如下式(I)所示:
第二方面,本发明还提供一种可用放射性核素标记的FAP和整合素αvβ3的双重靶向化合物,其结构中同时包含FAP和整合素αvβ3的特异性结合配体结构以及核素螯合结构,本发明将该结构记作FAPI-RGD结构,所述的化合物结构如下式(I-1)或式(I-2)所示,
第三方面,本发明提供一种放射性核素标记的FAP和整合素αvβ3的双重靶向化合物,它是由本发明第二方面所述的化合物标记了放射性核素得到的。
本发明所述的方案中,所述的放射性核素可以选自发射α射线的同位素、发射β射线的同位素、发射γ射线的同位素、发射俄歇电子的同位素或发射X射线的同位素等,例如18F、51Cr、67Ga、68Ga、111In、99mTc、186Re、188Re、139La、140La、175Yb、153Sm、166Ho、86Y、90Y、149Pm、165Dy、169Er、177Lu、47Sc、142Pr、159Gd、212Bi、213Bi、72As、72Se、97Ru、109Pd、105Rh、101mRh、119Sb、128Ba、123I、124I、131I、197Hg、211At、151Eu、153Eu、169Eu、201Tl、203Pb、212Pb、64Cu、67Cu、198Au、225Ac、227Th、89Zr或199Ag中的任意一种;更优选的放射性核素为18F、64Cu、68Ga、89Zr、90Y、111In、99mTc、177Lu、188Re或225Ac。
第四方面,本发明提供一种制备第二方面所述的双重靶向化合物及其放射性核素标记化合物(即本发明第三方面所述的双重靶向化合物)的方法,本发明提供的制备方法包括:
①6-羟基喹啉-4-羧酸的羧基首先与甘氨酸叔丁酯的氨基发生酰胺缩合反应;然后在酰胺缩合产物羟基位置通过烷基链连接Boc保护的哌嗪基;酸性条件下脱去Boc和叔丁基保护基,接着在哌嗪环引入Boc保护基;接着与(S)-吡咯烷-2-甲腈盐酸盐发生酰胺缩合反应;脱除Boc保护基后与N-Boc-3-[2-(2-氨基乙氧基)乙氧基]丙酸发生缩合反应;接着脱去Boc保护基,与 Fmoc-O-叔丁基-L-谷氨酸反应;脱去叔丁酯后,制备成活化酯,接着与带有氨基-二聚乙二醇的c(RGDfK)反应,得到双重靶向化合物;脱去Fmoc保护后与核素螯合剂反应,所述的核素螯合剂为1,4,7,10-四氮杂环十二烷-N,N',N,N'-四乙酸或1,4,7-三氮杂环壬烷-1,4,7-三乙酸;接着脱除螯合基团上的叔丁酯保护后得到可被放射性核素标记的双重靶向化合物,即本发明第二方面所述的双重靶向化合物。
②将①所得可被放射性核素标记的双重靶向化合物与含放射性核素的化合物按照现有的湿法标记方法或冻干法标记法反应,即可制备得到本发明第三方面所述的放射性核素标记的FAP和整合素αvβ3的双重靶向化合物。
第五方面,本发明提供一种药物组合物,所述的药物组合物包含本发明第一方面所述可靶向FAP和整合素αvβ3的双重靶向化合物、本发明第二方面所述的可用放射性核素标记的FAP和整合素αvβ3的双重靶向化合物、第三方面所述的放射性核素标记的FAP和整合素αvβ3的双重靶向化合物、或它们在药学上可接受的任意互变异构体、外消旋体、水合物、溶剂化物或盐。
第六方面,本发明还提供本发明第一方面所述可靶向FAP和整合素αvβ3的双重靶向化合物、第二方面所述的可用放射性核素标记的FAP和整合素αvβ3的双重靶向化合物、第三方面所述的放射性核素标记的FAP和整合素αvβ3的双重靶向化合物或第五方面所述的药物组合物在制备用于诊断或治疗动物或人类个体的以FAP和/或整合素αvβ3过度表达为特征的疾病的药物中的应用。
本发明所述的应用中,所述的以FAP和/或整合素αvβ3过度表达为特征的疾病包括但不限于:癌症、慢性炎症、动脉粥样硬化、纤维化、组织重塑和瘢痕病;优选地,所述的癌症进一步选自乳腺癌、胰腺癌、小肠癌、结肠癌、直肠癌、肺癌、头颈癌、卵巢癌、肝细胞癌、食道癌、下咽癌、鼻咽癌、喉癌、骨髓瘤细胞、膀胱癌、胆管细胞癌、透明细胞肾癌、神经内分泌肿瘤、致癌性骨软化症、肉瘤、CUP(原发性未知癌)、胸腺癌、胶质瘤、神经胶质瘤、星形细胞瘤、子宫颈癌或前列腺癌。
本发明提供的所述FAPI-RGD化合物结构,对于FAP靶点及整合素αvβ3靶点均具有较高的亲和力,能够协同靶向肿瘤中的FAP靶点及整合素αvβ3靶点,表现出较高的肿瘤摄取和肿瘤滞留时间,有望应用于诊断或治疗以FAP和/或整合素αvβ3过度表达为特征的疾病。
此外,本发明提供的所述FAPI-RGD化合物的制备方法反应路线简洁,操作简单,制备原料廉价易得,生产成本低,适宜工业化生产。
附图说明
图1为化合物7的核磁氢谱图。
图2为化合物7的核磁碳谱图。
图3为化合物7的质谱图。
图4为化合物8的质谱图。
图5为化合物9的质谱图。
图6为化合物12的质谱图。
图7为化合物13的质谱图。
图8为化合物14的质谱图。
图9为化合物15的质谱图。
图10为本发明中68Ga标记的FAPI-RGD(式I-1)配合物在生理盐水中的稳定性实验结果图。
图11为本发明中68Ga标记的FAPI-RGD(式I-1)配合物的细胞摄取和细胞结合实验结果图。
图12为本发明中68Ga标记的FAPI-RGD(式I-1)配合物以及单体68Ga-FAPI-02和68Ga-C(RGDfK)在HT1080-FAP荷瘤小鼠体内的MicroPET显像结果图。
图13为本发明中68Ga标记的FAPI-RGD(式I-1)配合物与C(RGDfK)或/和FAPI-02共注射30min后MicroPET成像结果及肿瘤及重要器官的摄取结果统计图。
图14为本发明中68Ga标记的FAPI-RGD(式I-1)配合物、18F-FDG和68Ga-FAPI46在胰腺癌、非小细胞肺癌、小细胞肺癌和鼻咽癌患者经静脉注射3小时后的PET/CT显像结果图。
具体实施方式
以下通过具体实施方式结合附图对本发明的技术方案进行进一步的说明和描述。
实施例1:化合物I-1的制备
化合物2的合成:
在100 mL烧瓶中分别投入化合物1(6-羟基喹啉-4-羧酸,1.89 g,10.0mmol)、甘氨酸叔丁酯(1.89 g,10.0mmol),HATU(3.8 g,10.0 mmol)和N,N-二异丙基乙胺(2.6 g,20.0mmol)依次投入至30 mL N,N-二甲基甲酰胺。反应混合物搅拌过夜,减压蒸馏除去溶剂,得到粗产物。经硅胶柱(二氯甲烷/甲醇=30:1)纯化得白色固体化合物2,产率87%。
化合物3的合成:
在100 mL烧瓶中分别将化合物2(1.51 g,5.0 mmol)、1-溴-3-氯丙烷(1.55 g,10.0 mmol)和碳酸钾(1.38 g,10.0 mmol)依次投入至50 mL N,N-二甲基甲酰胺中。将体系升温到60℃,保持体系60℃搅拌过夜,减压蒸馏除去溶剂,得到粗产物。经硅胶柱(二氯甲烷/甲醇=50:1)纯化得白色固体化合物3,产率63%。
化合物4的合成:
在100 mL烧瓶中分别将化合物3(0.76 g,2.0 mmol)、1-叔丁氧羰基哌嗪(0.55 g,3.0 mmol),和碘化钾(0.49 g,3.0 mmol)依次投入至30 mL 乙腈中。将体系升温到60℃,保持体系60℃搅拌过夜,减压蒸馏除去溶剂,得到粗产物。经硅胶柱(二氯甲烷/甲醇=30:1)纯化得白色固体化合物4,产率58%。
化合物5的合成:
在冰浴条件下,将化合物4(0.52 g,1.0 mmol)溶解在10mL二氯甲烷和三氟乙酸(体积比9:1)混合溶液中,将体系升温到室温反应2h,反应结束后减压蒸馏除去溶剂,用10mL的N,N-二甲基甲酰胺溶解,得到化合物5,备用。
化合物6的合成:
向化合物5的N,N-二甲基甲酰胺溶液中分别加入二碳酸二叔丁酯(0.22 g,1.0mmol)和N,N-二异丙基乙胺(0.39 g,3.0 mmol),室温搅拌过夜,减压蒸馏除去溶剂,得到粗产物。经硅胶柱(二氯甲烷/甲醇=10:1)纯化得白色固体化合物6,产率72%。
化合物7的合成:
在100 mL烧瓶中分别投入化合物6(0.47 g,1.0 mmol)、(S)-吡咯烷-2-甲腈盐酸盐(0.13 g,1.0 mmol),HATU(0.38 g,1.0 mmol)和N,N-二异丙基乙胺(0.26 g,2.0 mmol)依次投入至10 mL N,N-二甲基甲酰胺。反应混合物室温搅拌至反应结束,减压蒸馏除去溶剂,得到粗产物。经硅胶柱(二氯甲烷/甲醇=50:1)纯化得白色固体化合物7,产率85%。图1为化合物7的核磁氢谱,图2为化合物7的核磁碳谱,图3为化合物7的质谱图。
化合物8的合成:
将化合物7(2.50 g,4.5 mmol),对甲苯磺酸一水合物(2.58 g,13.6 mmol),25 mL的乙腈加入反应瓶中,65℃反应1h,TLC监测化合物7反应完全(甲醇:二氯甲烷=5:1),40℃减压蒸干。加入14mL 的DMF、DIPEA(3.05 g,23.6 mmol),25℃搅拌,反应编号(1),即化合物7的哌嗪脱保护得到中间体。将N-叔丁氧羰基-二聚乙二醇-羧酸(1.62 g,4.8 mmol),HATU(2.60 g, 6.8 mmol),10 mL的DMF加入另一反应瓶中,25℃反应30 min,反应编号(2),将反应(2)的反应溶液体系滴加到反应(1)体系中,反应1h。40℃减压蒸干,加入50 mL的纯化水,用DCM萃取两次,每次50 mL,合并DCM,用无水硫酸钠干燥,过滤,蒸干,得粗品,柱层析提纯,得目标物1.68 g。理论分子量709.3799,实测分子量709.38801,质谱结果与目标物一致。图4为化合物8的质谱图。
化合物9的合成:
将化合物8,对甲苯磺酸一水合物(1.61 g, 8.5 mmol),20 mL的乙腈加入反应瓶中,65℃反应1h,40℃减压蒸干。加入20 mL的DMF,DIPEA (1.83 g, 14.2 mmol),25℃搅拌,反应编号(1)。将Fmoc-O-叔丁基-L-谷氨酸(1.43 g, 3.4 mmol),HATU(1.29 g, 3.4mmol),20 mL的DMF加入另一反应瓶中,25℃反应30min,反应编号(2),将反应(2)的反应溶液体系滴加到反应(1)体系中,反应1h。40℃减压蒸干,得粗品,柱层析提纯,得目标物1.19g。理论分子量1016.5008,实测分子量1016.51094,质谱结果与目标物一致。图5为化合物9的质谱图。
化合物12的合成:
将c(RGDfK) (1.00 g, 1.7 mmol)、氨基叔丁酯-二聚乙二醇-琥珀酰亚胺酯(0.74g, 1.9 mmol)、DIPEA(0.44 g, 3.4 mmol)和20 mL的DMF加入反应瓶中,30℃反应20h。40℃减压蒸干,加入10 mL的甲醇,滴加60 mL的MTBE,析出固体,得到中间体11,抽滤,40℃真空干燥2h。将固体的中间体11加入反应瓶中,加入30 mL的TFA,1.5 mL的纯化水,30℃反应1h,降温至0-5℃,滴加200 mL的MTBE,0-5℃搅拌30min,抽滤,用MTBE淋洗,40℃真空干燥,得产品。理论分子量762.4024,实测分子量762.40768,质谱结果与目标物一致。图6为化合物12的质谱图。
化合物13的合成:
将化合物9,对甲苯磺酸一水合物(0.34 g, 1.8mmol),20 mL的乙腈加入反应瓶中,65℃反应4h,40℃减压蒸干。加入20 mL的DMF,DIPEA(0.36 g, 2.8 mmol),DCC(0.14 g,0.7 mmol),NHS(0.08 g,0.7 mmol),35℃反应15-20 h得到中间体10,降温至25℃,加入化合物12,反应1h,40℃减压蒸干,得粗品,制备液相纯化,得目标物66.5 mg。理论分子量1704.8300,实测分子量1704.84518,质谱结果与目标物一致。图7为化合物13的质谱图。
化合物14的合成:
将化合物13,0.5 mL的哌啶,2 mL的DMF加入反应瓶中,25℃反应1h,滴加10 mL的乙酸乙酯析晶,搅拌30min,抽滤,固体40℃真空干燥2h,得产品50.8 mg。将脱去Fmoc保护的化合物13溶解在2 mL 的DMF中,加入NOTA-2叔丁酯-NHS活化酯,DIPEA(0.010 g,0.08mmol),25℃反应1h,40℃减压蒸干,加入2 mL的乙酸乙酯,2 mL 的MTBE析晶,搅拌20 min,抽滤,固体40℃真空干燥,得产品43.2 mg。理论分子量1880.0196,实测分子量1880.0369,质谱结果与目标物一致。图8为化合物14的质谱图。
化合物15的合成:
将化合物14,2 mL的三氟乙酸加入反应瓶中,25℃反应1h,40℃减压蒸干,得粗品,用制备液相提纯,冻干,得产品化合物15,产率42%。理论分子量1767.8944,实测分子量1767.91036,质谱结果与目标物一致。图9为化合物15的质谱图。
上述步骤合成路线如下:
实施例2
实施例2的制备方法参考实例1,将上述实施例中NOTA-2叔丁酯-NHS活化酯替换为DOTA-3叔丁酯-NHS活化酯,得到如下的结构:
实施例3.放射性Ga-68标记FAPI-RGD式(I-1)配合物(68Ga-FAPI-RGD)的制备:
湿法:将约18.5~1850兆贝可(MBq)68GaCl3盐酸溶液(淋洗自锗镓发生器)加入到含0.5mL实施例1制备的结构如式(I-1)的化合物的醋酸-醋酸盐溶液(1.0g/L)的离心管中,置于37oC下反应20min。取一C18分离小柱,先用10mL无水乙醇缓慢淋洗,再用10mL水淋洗。用10mL水将标记液稀释后,上样到分离柱上,先用10mL水除去未标记的68Ga 离子,再用0.3mL10mM的HCl的乙醇溶液淋洗得到68Ga标记的FAPI-RGD配合物。该淋洗液经生理盐水稀释,并经无菌过滤后即得68Ga标记的FAPI-RGD配合物的注射液。
冻干法:将约18.5~1850兆贝可(MBq)68GaCl3盐酸溶液(淋洗自锗镓发生器)加入到含有式(I-1)化合物的冻干药盒中,混匀后37℃下反应20min。取一C18分离小柱,先用10mL无水乙醇缓慢淋洗,再用10mL水淋洗。用10mL水将标记液稀释后,上样到分离柱上,先用10mL水除去未标记的68Ga离子,再用0.3mL 10mM的HCl的乙醇溶液淋洗得到配合物淋洗液。该淋洗液经生理盐水稀释,并经无菌过滤后即得68Ga标记的FAPI-RGD配合物的注射液。
实验例分析及应用效果
1、68Ga标记的式(I-1)FAPI-RGD的配合物的稳定性分析
移取20μL实施例3制备的68Ga-FAPI-RGD (3.7MBq活度/20μL)的溶液加入到含有100μL生理盐水或PBS(pH=7.4)的离心管中,在37℃条件下共孵育0.5h、1h和4h,共孵育溶液。取20μL共孵育溶液,过0.22μm针式滤膜,采用HPLC分析放射化学纯度。测试结果如图10所示, 68Ga-FAPI-RGD在生理盐水中孵育后,未见明显分解,放射化学纯度均大于99%,说明本发明制备的68Ga-FAPI-RGD稳定性优异。
2、68Ga标记的式(I-1)FAPI-RGD的配合物细胞实验分析
在HT1080-FAP肿瘤细胞中进行68Ga-FAPI-RGD的细胞摄取实验,测试结果如图11中的A部分所示,68Ga-FAPI-RGD具有快速的细胞摄取,在孵育30分钟时,摄取达到最大并保持在相似摄取水平长达 2 小时。此外,阻断实验证实,68Ga-FAPI-RGD的细胞摄取可以被C(RGDfK) 或FAPI-02部分抑制,可以被FAPI-RGD完全阻断(参见图11中的A部分)。在HT1080-FAP和U87MG肿瘤细胞中进行了细胞结合实验,测试结果分别如图11中的B和C所示,在HT1080-FAP细胞实验中,测得68Ga-FAPI-RGD和68Ga-FAPI-02的IC50两分别为11.17 nM和4.14nM。HT1080-FAP细胞实验中,测得68Ga-FAPI-RGD和68Ga- C(RGDfK)的IC50两分别为18.93 nM和11.49nM组。实验结果表明FAPI-RGD与相应的单体相比,与其相应受体FAP和整合素αvβ3具有相似的亲和力。
3、68Ga标记的式(I)FAPI-RGD的配合物在荷瘤小鼠体内的MicroPET显像
按实施例3的方法制备68Ga-FAPI-RGD,在HT1080-FAP荷瘤小鼠中,针对随机分组的小鼠,分别经尾静脉注射7.4 MBq的68Ga-FAPI-RGD、68Ga-FAPI-02和68Ga-C(RGDfK),然后在异氟烷麻醉下,68Ga-FAPI-RGD组分别于给药后0~240 min进行MicroPET显像,其余组分别于给药后0~120 min进行MicroPET显像,结果见图12。图12中A、C和E分别显示了上述三组小鼠静脉注射后不同时间的HT1080-FAP荷瘤小鼠(n=3)的MicroPET最大密度投影图像,B、D和F分别体现了上述三组小鼠注射后各器官或组织(血、肝、肾、肿瘤和肌肉)在不同时间点的摄取,每组中三个摄取量从左至右分别对应注射后0.5h、1h和2h。图12显示了在采集成像的时间点,肿瘤清晰可见,并且68Ga-FAPI-RGD的肿瘤摄取高于单体68Ga-FAPI-02和68Ga-C(RGDfK)的肿瘤摄取。68Ga-FAPI-RGD在体内特异性结合整合素αvβ3和FAP的性能通过阻断实验得到证实。将上述68Ga-FAPI-RGD与C(RGDfK)或FAPI-02共注射到HT1080-FAP荷瘤小鼠体内,其MicroPET显像结果图及器官摄取结果如图13所示。图13中,A的四个影像从左至右分别对应单独注射68Ga-FAPI-RGD、68Ga-FAPI-RGD与C(RGDfK)共注射、68Ga-FAPI-RGD与FAPI-02共注射、68Ga-FAPI-RGD 与C(RGDfK)和FAPI-02共注射得到的影像;B和C分别体现了上述四组不同注射方式注射后小鼠各器官或组织(血、肝、肾、肿瘤和肌肉)对68Ga-FAPI-RGD 的摄取和靶/非靶比值,B和C中的每种器官或组织中四个柱状图形从左至右分别对应A中的四种注射方式。从图13中可以看到,与68Ga-FAPI-RGD共注射RGD或FAPI-02均能降低肿瘤对68Ga-FAPI-RGD的摄取,与68Ga-FAPI-RGD共注射C(RGDfK)+FAPI-02则进一步降低肿瘤对68Ga-FAPI-RGD的摄取,阻断实验证实68Ga-FAPI-RGD在体内能够通过结合整合素αvβ3和FAP实现肿瘤特异性靶向。
4、68Ga标记的式(I-1)FAPI-RGD的配合物在肿瘤病人上的PET/CT显像
经厦门大学第一附属医院临床研究伦理委员会批进行68Ga-FAPI-RGD的临床试验,所有受试者均签署书面知情同意书,包括一名胰腺癌患者,一名非小细胞肺癌患者,一名小细胞肺癌患者和一名鼻咽癌患者。根据受试者体重计算静脉注射68Ga-FAPI-RGD的剂量(1.8~2.2MBq[0.05~0.06mCi]/kg)。在静脉注射3小时后,使用混合PET/CT扫描仪(DiscoveryMI,GE Healthcare,Milwaukee,WI,USA)获取数据,显像结果如图14。使用在经轴图像上绘制的感兴趣区域(ROI)自动计算最大标准摄取值(SUVmax)。双靶点靶向的68Ga-FAPI-RGD在不同类型肿瘤中的SUVmax均高于FAP蛋白单靶向的68Ga-FAPI-46,SUVmax升高约30-50%,证实了双靶点靶向的设计可以提升肿瘤中的有效受体数量和利用效率进而提升肿瘤摄取。
综上所述,本发明开发了FAPI-RGD结构,对于FAP靶点及整合素αvβ3靶点均具有较高的亲和力,能够协同靶向肿瘤中的FAP靶点及整合素αvβ3靶点,表现出优异的代谢动力学、较高的肿瘤摄取和肿瘤滞留时间,有望应用于诊断或治疗以FAP和/或整合素αvβ3过度表达为特征的疾病。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (11)
3.制备权利要求2所述的可被放射性核素标记的双重靶向化合物的方法,其特征在于,包括以下步骤:6-羟基喹啉-4-羧酸的羧基首先与甘氨酸叔丁酯的氨基发生酰胺缩合反应;然后在酰胺缩合产物羟基位置通过烷基链连接Boc保护的哌嗪基;酸性条件下脱去Boc和叔丁基保护基,接着在哌嗪环引入Boc保护基;接着与(S)-吡咯烷-2-甲腈盐酸盐发生酰胺缩合反应;脱除Boc保护基后与N-Boc-3-[2-(2-氨基乙氧基)乙氧基]丙酸发生缩合反应;接着脱去Boc保护基,与 Fmoc-O-叔丁基-L-谷氨酸反应;脱去叔丁酯后,制备成活化酯,接着与带有氨基-二聚乙二醇的c(RGDfK)反应,得到双重靶向化合物;脱去Fmoc保护后与核素螯合剂反应,所述的核素螯合剂为1,4,7,10-四氮杂环十二烷-N,N',N,N'-四乙酸或1,4,7-三氮杂环壬烷-1,4,7-三乙酸;接着脱除螯合基团上的叔丁酯保护后得到一种可被放射性核素标记的双重靶向化合物。
4.一种放射性核素标记的双重靶向化合物,其特征在于:它是权利要求2所述的任意一种可被放射性核素标记的双重靶向化合物标记了放射性核素得到的;所述的放射性核素选自发射α射线的同位素、发射β射线的同位素、发射γ射线的同位素、发射俄歇电子的同位素或发射X射线的同位素。
5.如权利要求4所述的放射性核素标记的双重靶向化合物,其特征在于:所述的放射性核素选自18F、51Cr、64Cu、67Cu、67Ga、68Ga、89Zr、111In、99mTc、186Re、188Re、139La、140La、175Yb、153Sm、166Ho、86Y、90Y、149Pm、165Dy、169Er、177Lu、47Sc、142Pr、159Gd、212Bi、213Bi、72As、72Se、97Ru、109Pd、105Rh、101mRh、119Sb、128Ba、123I、124I、131I、197Hg、211At、151Eu、153Eu、169Eu、201Tl、203Pb、212Pb、198Au、225Ac、227Th或199Ag中的任意一种。
6.如权利要求4所述的放射性核素标记的双重靶向化合物,其特征在于:所述的放射性核素选自18F、64Cu、68Ga、89Zr、90Y、111In、99mTc、177Lu、188Re或225Ac。
7.制备权利要求4所述放射性核素标记的双重靶向化合物的方法,其特征在于,包括:将权利要求2所述的可被放射性核素标记的双重靶向化合物与含放射性核素的化合物按照湿法标记方法或冻干法标记法反应,即可制备得到所述的放射性核素标记的双重靶向化合物。
8.一种药物组合物,其特征在于:包含权利要求1所述的双重靶向化合物、权利要求2所述的可被放射性核素标记的双重靶向化合物、权利要求4所述的放射性核素标记的双重靶向化合物、或它们在药学上可接受的水合物、溶剂化物或盐。
9.权利要求1所述的双重靶向化合物、权利要求2所述的可被放射性核素标记的双重靶向化合物、权利要求4所述的放射性核素标记的双重靶向化合物、或它们在药学上可接受的水合物、溶剂化物或盐、或权利要求8所述的药物组合物中的任意一种在制备用于诊断或治疗动物或人类个体的以FAP和/或整合素αvβ3过度表达为特征的疾病的药物中的应用。
10.如权利要求9所述的应用,其特征在于:所述的以FAP和/或整合素αvβ3过度表达为特征的疾病包括:癌症、慢性炎症、动脉粥样硬化或瘢痕病。
11.如权利要求10所述的应用,其特征在于:所述的癌症选自乳腺癌、胰腺癌、小肠癌、结肠癌、直肠癌、肺癌、头颈癌、卵巢癌、肝细胞癌、食道癌、下咽癌、鼻咽癌、喉癌、骨髓瘤细胞、膀胱癌、胆管细胞癌、透明细胞肾癌、神经内分泌肿瘤、致癌性骨软化症、肉瘤、原发性未知癌、胸腺癌、胶质瘤、神经胶质瘤、星形细胞瘤、子宫颈癌或前列腺癌。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211201081.2A CN115286697B (zh) | 2022-09-29 | 2022-09-29 | 一种双重靶向化合物及其制备方法和应用 |
JP2023536546A JP2023551741A (ja) | 2022-09-29 | 2022-12-09 | 二重標的化化合物及びその調製方法と応用 |
CA3232196A CA3232196A1 (en) | 2022-09-29 | 2022-12-09 | Dual-targeting compound and preparation method and application thereof |
AU2022402959A AU2022402959B2 (en) | 2022-09-29 | 2022-12-09 | Dual-targeting compound, and preparation method therefor and use thereof |
KR1020237020530A KR102658933B1 (ko) | 2022-09-29 | 2022-12-09 | 이중 표적화 화합물 및 이의 제조 방법과 응용 |
EP22900722.4A EP4253402A4 (en) | 2022-09-29 | 2022-12-09 | DOUBLE TARGETED COMPOUND, PREPARATION METHOD AND USE THEREOF |
PCT/CN2022/137823 WO2023098920A1 (zh) | 2022-09-29 | 2022-12-09 | 一种双重靶向化合物及其制备方法和应用 |
ZA2024/02726A ZA202402726B (en) | 2022-09-29 | 2024-04-09 | Dual-targeting compound and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211201081.2A CN115286697B (zh) | 2022-09-29 | 2022-09-29 | 一种双重靶向化合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115286697A CN115286697A (zh) | 2022-11-04 |
CN115286697B true CN115286697B (zh) | 2022-12-13 |
Family
ID=83834000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211201081.2A Active CN115286697B (zh) | 2022-09-29 | 2022-09-29 | 一种双重靶向化合物及其制备方法和应用 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4253402A4 (zh) |
JP (1) | JP2023551741A (zh) |
KR (1) | KR102658933B1 (zh) |
CN (1) | CN115286697B (zh) |
AU (1) | AU2022402959B2 (zh) |
CA (1) | CA3232196A1 (zh) |
WO (1) | WO2023098920A1 (zh) |
ZA (1) | ZA202402726B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115286697B (zh) * | 2022-09-29 | 2022-12-13 | 烟台蓝纳成生物技术有限公司 | 一种双重靶向化合物及其制备方法和应用 |
CN115505032A (zh) * | 2022-09-29 | 2022-12-23 | 烟台蓝纳成生物技术有限公司 | 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法和应用 |
CN115433261B (zh) * | 2022-11-07 | 2023-01-13 | 烟台蓝纳成生物技术有限公司 | 一种rgd二聚体化合物及其制备方法和应用 |
CN115583989B (zh) * | 2022-12-09 | 2023-02-28 | 烟台蓝纳成生物技术有限公司 | 一种靶向sstr2的化合物及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
CN110023490A (zh) * | 2016-10-19 | 2019-07-16 | 塞勒克提斯公司 | 用于改善的免疫细胞疗法的靶向基因插入 |
SG11202007180QA (en) * | 2018-02-06 | 2020-08-28 | Univ Heidelberg | Fap inhibitor |
DE102018126558A1 (de) * | 2018-10-24 | 2020-04-30 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Markierungsvorläufer mit Quadratsäure-Kopplung |
CA3155027A1 (en) * | 2019-09-30 | 2021-04-08 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
AU2021226147A1 (en) * | 2020-02-25 | 2022-09-22 | Provincial Health Services Authority | Chelator compositions for radiometals and methods of using same |
US20230272056A1 (en) * | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
CA3190091A1 (en) * | 2020-08-20 | 2022-02-24 | Dexing Zeng | Small molecule albumin binders |
CN113880810B (zh) * | 2021-09-24 | 2023-02-28 | 厦门大学 | 一种核素标记的配合物及其制备方法和应用 |
CN114874335B (zh) * | 2022-05-06 | 2024-04-19 | 北京大学深圳研究生院 | 三靶点可调控car免疫细胞的组合物及其应用 |
CN115286697B (zh) * | 2022-09-29 | 2022-12-13 | 烟台蓝纳成生物技术有限公司 | 一种双重靶向化合物及其制备方法和应用 |
-
2022
- 2022-09-29 CN CN202211201081.2A patent/CN115286697B/zh active Active
- 2022-12-09 AU AU2022402959A patent/AU2022402959B2/en active Active
- 2022-12-09 CA CA3232196A patent/CA3232196A1/en active Pending
- 2022-12-09 KR KR1020237020530A patent/KR102658933B1/ko active IP Right Grant
- 2022-12-09 EP EP22900722.4A patent/EP4253402A4/en active Pending
- 2022-12-09 JP JP2023536546A patent/JP2023551741A/ja active Pending
- 2022-12-09 WO PCT/CN2022/137823 patent/WO2023098920A1/zh active Application Filing
-
2024
- 2024-04-09 ZA ZA2024/02726A patent/ZA202402726B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR102658933B1 (ko) | 2024-04-18 |
EP4253402A1 (en) | 2023-10-04 |
EP4253402A4 (en) | 2023-10-04 |
WO2023098920A1 (zh) | 2023-06-08 |
AU2022402959B2 (en) | 2023-08-03 |
JP2023551741A (ja) | 2023-12-12 |
ZA202402726B (en) | 2024-04-24 |
KR20240046416A (ko) | 2024-04-09 |
CA3232196A1 (en) | 2023-06-08 |
CN115286697A (zh) | 2022-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115286697B (zh) | 一种双重靶向化合物及其制备方法和应用 | |
US7226577B2 (en) | Gastrin releasing peptide compounds | |
KR101243016B1 (ko) | 진단용 화합물 | |
CA3090812A1 (en) | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer | |
JP2022513256A (ja) | デュアルモード18f標識セラノスティック化合物及びその使用 | |
CN111065646A (zh) | 放射性药物 | |
JP6164556B2 (ja) | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 | |
CN109438517B (zh) | 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法 | |
CN115260160B (zh) | 一种靶向成纤维细胞活化蛋白fap的化合物及其制备方法和应用 | |
EP3710068A1 (en) | A double-labeled probe for molecular imaging and use thereof | |
WO2023098072A1 (zh) | 靶向Nectin-4的双环肽核素配体与探针 | |
WO2024067531A1 (zh) | 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法和应用 | |
CN105579434A (zh) | 基于乙烯基砜的18f标记组合物和方法及其用途 | |
WO2023236778A1 (zh) | 一种三功能化合物及其用途 | |
WO2020210919A1 (en) | Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy | |
JP2004526671A (ja) | 診断および治療への適用において使用するための抗酸化剤の金属キレート配位子との結合体 | |
JP2008308423A (ja) | 両親媒性の高分子配位子によって安定化された高分子錯体および検査用組成物および医薬組成物 | |
WO2023044965A1 (zh) | 一种SNAP-tag探针及其制备方法与应用 | |
CN116751259A (zh) | 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法 | |
CA3208649A1 (en) | Precursor and radiotracer for neuroendocrine theranostics | |
US20240131205A1 (en) | Dual-targeting compound and preparation method and application thereof | |
WO2024099245A1 (zh) | 一种rgd二聚体化合物及其制备方法和应用 | |
CN115433261B (zh) | 一种rgd二聚体化合物及其制备方法和应用 | |
CN115368342B (zh) | 成纤维细胞活性蛋白抑制剂、其放射性核素标记物及制备方法和应用 | |
WO2024046469A1 (zh) | 环肽及其制备方法、包括其的复合物、及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |